Compare TSAT & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TSAT | STTK |
|---|---|---|
| Founded | 1969 | 2016 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 697.5M | 792.9M |
| IPO Year | 2021 | 2020 |
| Metric | TSAT | STTK |
|---|---|---|
| Price | $44.96 | $6.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 7 |
| Target Price | ★ $37.00 | $10.00 |
| AVG Volume (30 Days) | 197.2K | ★ 773.5K |
| Earning Date | 05-05-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 53.02 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $23.01 | $1.59 |
| 52 Week High | $61.54 | $8.33 |
| Indicator | TSAT | STTK |
|---|---|---|
| Relative Strength Index (RSI) | 47.07 | 44.39 |
| Support Level | $41.65 | $5.87 |
| Resistance Level | $46.56 | $7.75 |
| Average True Range (ATR) | 2.44 | 0.34 |
| MACD | -0.60 | -0.12 |
| Stochastic Oscillator | 18.22 | 11.51 |
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. The company has two operating segments: GEO services (GEO) segment that refers to the operation of the fleet of GEO satellite and LEO services (LEO) segment that refers to the deployment and operation of the Telesat Lightspeed constellation Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.